Herpes Research Today is a free monthly online journal that collates and summarizes the latest research about Herpes, including details on herpes simplex virus (hsv), genital, oral, symptoms, treatment.

Development of a therapeutic vaccine for HSV-2.

Hosken NA

Corixa Corporation, 1900 9th Avenue, Suite 1100, Seattle, WA 98101, USA. hoskenn@zgi.com

A therapeutic vaccine for genital herpes is clearly needed. Vaccines recently developed for HSV-2 in humans have been aimed at eliciting CD4+ T cell responses and neutralizing antibody responses to two HSV-2 glycoproteins (gB and gD). These vaccines have had no therapeutic effect against HSV-2 in human clinical trials. To enable development of an efficacious vaccine, Corixa Corporation has made a major effort to identify novel antigens that can be recognized by human HSV-2-specific CD8+ and CD4+ T cells. Corixa Corporation's proprietary adjuvants and delivery systems, when combined with appropriate antigens, may allow the development of an effective therapeutic vaccine for HSV-2.

Published 9 March 2005 in Vaccine, 23(17): 2395-8.
Full-text of this article is available online (may require subscription).

© 2004-2008 Herpes Research Today. All Rights Reserved.